Literature DB >> 4606364

Combined T and B cell acute lymphoblastic leukaemia.

D G Haegert, J C Cawley, A Karpas, A H Goldstone.   

Abstract

A case of acute lymphoblastic leukaemia in a 17-year-old male is described. The patient had many distinctive features including a very high blast cell count, prominent lymphadenopathy and hepatosplenomegaly, thymic mass, and a fulminant clinical course. Immunological studies on the blast cells using a variety of techniques showed the presence of two distinct subpopulations, one having the surface characteristics of thymus-dependent (T) lymphoid cells and the other those of bursa-equivalent (B) lymphoid cells. The case therefore represents the first example of a combined T and B cell acute leukaemia.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4606364      PMCID: PMC1612151          DOI: 10.1136/bmj.4.5936.79

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  22 in total

1.  Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes.

Authors:  J Minowada; T Onuma; G E Moore
Journal:  J Natl Cancer Inst       Date:  1972-09       Impact factor: 13.506

Review 2.  T and B lymphocytes and immune responses.

Authors:  M C Raff
Journal:  Nature       Date:  1973-03-02       Impact factor: 49.962

3.  Immunoglobulins on the surface of neoplastic lymphocytes.

Authors:  A C Aisenberg; K J Bloch
Journal:  N Engl J Med       Date:  1972-08-10       Impact factor: 91.245

4.  Isolation of normal T cells in chronic lymphatic leukaemia.

Authors:  J Wybran; S Chantler; H H Fudenberg
Journal:  Lancet       Date:  1973-01-20       Impact factor: 79.321

5.  Identification of human T and B lymphocytes in normal peripheral blood and in chronic lymphocytic leukaemia.

Authors:  J D Wilson; G J Nossal
Journal:  Lancet       Date:  1971-10-09       Impact factor: 79.321

6.  Binding of sheep red blood cells to a large population of human lymphocytes.

Authors:  W H Lay; N F Mendes; C Bianco; V Nussenzweig
Journal:  Nature       Date:  1971-04-23       Impact factor: 49.962

7.  Receptor sites for complement on certain human peripheral blood lymphocytes.

Authors:  G Michlmayr; H Huber
Journal:  J Immunol       Date:  1970-09       Impact factor: 5.422

8.  Receptors for complement and immunoglobulin on human leukemic cells and human lymphoblastoid cell lines.

Authors:  E M Shevach; R Herberman; M M Frank; I Green
Journal:  J Clin Invest       Date:  1972-08       Impact factor: 14.808

9.  A population of lymphocytes bearing a membrane receptor for antigen-antibody-complement complexes. I. Separation and characterization.

Authors:  C Bianco; R Patrick; V Nussenzweig
Journal:  J Exp Med       Date:  1970-10-01       Impact factor: 14.307

10.  Surface markers on human T and B lymphocytes. I. A large population of lymphocytes forming nonimmune rosettes with sheep red blood cells.

Authors:  M Jondal; G Holm; H Wigzell
Journal:  J Exp Med       Date:  1972-08-01       Impact factor: 14.307

View more
  4 in total

1.  Studies on the immune status of children with acute lymphocytic leukaemia. I. Early phase before and after first remission.

Authors:  W H Hitzig; H J Plüss; P Joller; U Pilgrim; H Tacier-Eugster; M Jakob
Journal:  Clin Exp Immunol       Date:  1976-12       Impact factor: 4.330

2.  Subset derivation of T-cell acute lymphoblastic leukemia in man.

Authors:  E L Reinherz; L M Nadler; S E Sallan; S F Schlossman
Journal:  J Clin Invest       Date:  1979-08       Impact factor: 14.808

3.  Phagocytic peripheral blood monocytes from rabbits and humans express membrane receptors specific for IgM molecules: evidence that incubation with neuraminidase exposes cryptic IgM (Fc) receptors.

Authors:  D G Haegert
Journal:  Clin Exp Immunol       Date:  1979-03       Impact factor: 4.330

4.  Surface membrane determinants on childhood acute lymphocytic leukemia cells: immunoglobulin, Fc and C3 receptors.

Authors:  E C Esber; N Movassaghi; S L Leikin
Journal:  Clin Exp Immunol       Date:  1978-06       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.